Prognostic potential of liver injury in patients with dilated cardiomyopathy: a retrospective study

Table 3 Univariable Cox regression analyses for all-cause mortality in patients with dilated cardiomyopathy

Variable	Before baseline adjustment using PSM			After baseline adjustment using PSM
Variable	HR	95% CI	P value	HR	95% CI	P value
Age	1.005	0.993–1.018	0.383	1.006	0.990–1.023	0.435
Male	1.049	0.732–1.503	0.796	1.075	0.624–1.854	0.794
BMI	0.943	0.904–0.984	0.007	0.965	0.914–1.019	0.199
Hypertension	0.789	0.489–1.272	0.331	0.827	0.399–1.714	0.609
Diabetes mellitus	1.525	1.025–2.268	0.037	1.354	0.817–2.242	0.239
Atrial fibrillation	0.988	0.665–1.468	0.953	0.779	0.451–1.343	0.369
NYHA class
IV/II–III	1.556	1.144–2.118	0.005	1.405	0.909–2.173	0.126
SBP	0.972	0.963–0.982	< 0.001	0.972	0.957–0.987	< 0.001
BUN	1.064	1.029–1.101	< 0.001	1.036	0.997–1.077	0.074
eGFR ≥ 60 mL/min/1.73 m²	0.649	0.402–1.047	0.076	0.813	0.450–1.471	0.494
AST	1.002	1.000–1.004	0.021	1.000	0.998–1.003	0.805
ALT	1.001	1.000–1.002	0.168	1.000	0.998–1.001	0.773
Total bilirubin	1.005	1.002–1.008	0.004	1.001	0.997–1.005	0.610
Lg (NT-proBNP)	3.533	2.451–5.093	< 0.001	2.698	1.566–4.649	< 0.001
QRS	1.005	1.000–1.010	0.071	1.006	0.999–1.013	0.096
LAD	1.041	1.021–1.062	< 0.001	1.028	1.001–1.056	0.041
LVEDD	1.044	1.027–1.061	< 0.001	1.036	1.014–1.059	0.001
LVEF < 35%	1.637	1.173–2.283	0.004	2.000	1.228–3.260	0.005
RAS inhibitor	0.548	0.368–0.814	0.003	0.587	0.365–0.943	0.028
Beta-blocker	0.900	0.563–1.438	0.660	0.964	0.464–2.004	0.922
Spironolactone	0.761	0.374–1.549	0.451	0.699	0.283–1.727	0.438
ICD/CRT	0.837	0.393–1.786	0.646	1.137	0.416–3.108	0.802
Liver injury	2.583	1.855–3.597	< 0.001	1.677	1.082–2.599	0.021

ISSN: 2047-783X